

Peri-Implantitis and Prosthetic failures: Prevention, Diagnosis and Management Strategies in Prosthodontics

¹Dr Vandana Rai, MDS in Prosthodontics, Crown and Bridge, Sree Balaji Dental College and Hospital Institute, Chennai, India.

²Dr Shruti Shetty, BDS , Sarvodaya Dental Clinic, Mumbai, India.

³Dr Varsha Aher, MDS OMDR, Goregaon Dental Centre, Mumbai, India.

⁴Dr Jasdeep Kaur Cheema, BDS, DDS, FPPA, Alumini University of the Pacific Arthur A Dugoni School of Dentistry, San Francisco, USA.

Corresponding Author: Dr Vandana Rai, MDS in Prosthodontics, Crown and Bridge, Sree Balaji Dental College and Hospital Institute, Chennai, India.

Citation of this Article: Dr Vandana Rai, Dr Shruti Shetty, Dr Varsha Aher, Dr Jasdeep Kaur Cheema, “Peri-Implantitis and Prosthetic failures: Prevention, Diagnosis and Management Strategies in Prosthodontics”, IJDSIR- August – 2025, Volume – 8, Issue – 4, P. No. 08 – 19.

Copyright: © 2025, Dr Vandana Rai, et al. This is an open access journal and article distributed under the terms of the creative common’s attribution non-commercial License. Which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given, and the new creations are licensed under the identical terms.

Type of Publication: Review Article

Conflicts of Interest: Nil

Abstract

Peri-implantitis, an inflammatory condition affecting the tissues surrounding dental implants, has become a growing concern in modern implant dentistry due to its increasing prevalence and complex etiology. The management of this condition presents significant clinical challenges, stemming from limitations in early diagnosis, variability in disease progression, and the lack of universally accepted treatment protocols. In recent years, considerable advancements have been made in both non-surgical and surgical treatment modalities. Innovations such as laser therapy, air-abrasive devices, photodynamic therapy, and the use of novel biomaterials in regenerative procedures have shown promise in improving clinical outcomes. Additionally, emerging diagnostic techniques involving molecular biomarkers and advanced imaging

are contributing to earlier and more accurate detection of disease activity. Despite these developments, managing peri-implantitis remains difficult due to the multifactorial nature of the disease, patient-related risk factors, and inconsistent success rates of treatment methods. Long-term stability is often elusive, and recurrence is not uncommon. This narrative review discusses the current strategies, recent innovations, and persisting obstacles in the management of peri-implantitis, highlighting the need for continued research and the development of standardized, evidence-based clinical protocols.

Keywords: Peri-Implantitis, Etiology, Micro Surface, Ultrasonic Scaler.

Introduction

The 2017 World Workshop consensus defined peri-implantitis as a plaque-induced pathological condition

affecting the tissues surrounding dental implants, characterized by inflammation in the peri-implant mucosa and a progressive loss of supporting bone¹. It is considered the implant equivalent of periodontitis, where microbial colonization results in destructive inflammatory responses, compromising the long-term stability of the implant². The disease process typically starts as peri-implant mucositis, which is a reversible inflammation of the soft tissues surrounding an implant without bone loss. If untreated, peri-implant mucositis can progress to peri-implantitis, characterized by irreversible peri-implant bone resorption and a deepening of peri-implant pockets³. Unlike natural teeth, implants lack a periodontal ligament, which may limit their ability to resist bacterial insults and inflammatory processes.

Although patients often expect dental implants to last indefinitely, a Swedish study found that nearly half of implant recipients experienced peri-implantitis within a decade⁴. Additionally, the growing prevalence of implant surgery has led to a significant rise in peri-implantitis cases. Unlike periodontitis, peri-implantitis progresses more rapidly and unpredictably, making treatment outcomes less certain⁵. In natural teeth, collagen fibers in the connective tissue insert perpendicularly into the cementum, creating a strong mucosal seal that acts as a biological barrier. However, in dental implants, these fibers align parallel to the abutment surface, weakening the mucosal seal and reducing its protective function⁶. The macro and micro surface geometry of implant fixtures hinders complete decontamination, lowering treatment success rates.

Various treatment approaches for peri-implantitis have been adapted from periodontitis management. Mombelli and Lang proposed cumulative interceptive supportive therapy, highlighting that peri-implantitis treatment is a continuous process involving multiple therapeutic steps

rather than a single procedure⁷. Several studies have examined the factors contributing to peri-implantitis, resulting in the suggestion of treatment protocols that consider these variables^{8,9,10}. Sinjab et al. specifically highlighted the role of keratinized gingiva around implants, arguing that its presence is crucial for implant stability. They proposed that soft-tissue augmentation procedures, such as grafting, are necessary to effectively manage peri-implant diseases and improve long-term implant success⁹. Monje proposed a decision tree for addressing failed implants, offering surgical solutions based on peri-implant defect configuration. The ITI Treatment Guide (Volume 13) outlines a peri-implantitis protocol that combines nonsurgical and surgical treatments, followed by re-evaluation^{8,10}. Treatment approaches for peri-implantitis must evolve as new scientific evidence emerges. For instance, nonsurgical therapy was previously considered ineffective due to access limitations¹¹. Recent research has demonstrated improved success rates in peri-implantitis treatment when nonsurgical therapy is paired with adjunctive antibiotics, highlighting its effectiveness compared to earlier approaches¹². A risk assessment tool has been introduced to evaluate individual peri-implantitis risk, focusing on the key factors that contribute to the disease's development¹³. The aim of this narrative review is to explore the management of peri-implantitis, highlighting current treatment options, advancements, and challenges, while proposing an updated treatment flowchart based on the latest scientific evidence.



Figure 1

Failing implants versus failed implants

The phrase “ailing, failing, and failed” was first applied to dental implants by Meffert¹⁴. According to current diagnostic criteria for peri-implant disease, an **ailing** implant is affected by peri-implant mucositis. A **failing** implant has peri-implantitis but still holds the potential for recovery. In contrast, a **failed** implant experiences severe peri-implantitis, necessitating its removal.




Figure 2 and 3

Implants that exhibit mobility due to complete loss of osseointegration or fractures should be removed. Histological analysis of extracted implants with mobility has shown a total loss of bone-implant contact when the implant stability quotient (ISQ) falls to 40 or below¹⁵.

The criteria for implant removal differ among clinicians. According to Volume 13 of the ITI Treatment Guide, the decision to remove an implant should be based on the extent of the defect and should be considered when the esthetic outcome is likely to be significantly affected⁸.

Researchers recommend implant removal when bone loss exceeds 50%, as this helps eliminate inflammation and prevent further bone loss, creating a better environment for future rehabilitation¹⁶. Studies indicate that the failure rate of peri-implantitis treatment is 20 times higher in cases with $\geq 50\%$ alveolar bone loss compared to those with $\leq 25\%$ bone loss¹⁷. After implant removal, a second implant placement remains a viable option, with a reported survival rate of approximately 88%. However, implant failure is influenced by patient-specific factors, making it essential to manage risk factors before surgery. Additionally, ridge augmentation is often required to compensate for alveolar bone loss resulting from peri-implantitis or implant removal¹⁸.

Nonsurgical treatment for peri-implantitis

Peri-implant mucositis is the stage that precedes peri-implantitis, similar to how gingivitis progresses to periodontitis². Managing peri-implant mucositis follows the principles of periodontal disease treatment and can serve as primary prevention for peri-implantitis¹⁹. Nonsurgical treatment is effective for peri-implant mucositis, but when the condition advances to peri-implantitis, nonsurgical methods often have limited success. Visual and instrumental access may be hindered by the prosthetic structure and bone defects, making surgical interventions necessary for adequate treatment^{11,20}. To overcome these limitations, adjunctive measures to mechanical debridement have been explored, providing a less invasive approach for both clinicians and patients. Both periodontal and peri-implant diseases share a common etiology as plaque-induced inflammatory

conditions, with high levels of Gram-negative and anaerobic bacteria²¹. Studies show that adjunctive antibiotic therapy improves nonsurgical treatment for peri-implantitis, based on its success in periodontal disease management^{12,22}.

Narts et al. observed radiologic bone gain and inflammation resolution with nonsurgical treatment using an ultrasonic scaler, glycine air abrasives, and supportive maintenance therapy every 3–6 months²². Park et al. found a significantly higher success rate in peri-implantitis treatment by combining local metronidazole and minocycline with nonsurgical treatment. The use of minocycline and the minocycline-metronidazole combination with mechanical debridement resulted in success rates of 20.5% and 31.6%, respectively, compared to 2.7% for debridement alone. However, adjunctive antibiotics carry a temporary risk of antibiotic resistance, requiring careful dosing and duration. Studies also reported successful long-term outcomes with nonsurgical treatment, using systemic metronidazole and 0.12% chlorhexidine gel. At a 4.5-year follow-up, the mean radiologic bone loss was reduced by 2.6 mm, and probing depth decreased by 4.7 mm. Poorly contoured restorations that hinder plaque control increase peri-implantitis risk¹². Adjusting implant restorations to improve oral hygiene access enhances nonsurgical treatment outcomes and prevents inflammation rebound²³. Removing prosthetic structures before decontamination significantly improves treatment efficacy, with a recent trial showing doubled success rates when combined with mechanical debridement and systemic metronidazole²⁴.




Figure 4: Non surgical treatment for peri-implantitis

Surgical treatment for peri-implantitis

Surgical treatment is necessary when inflammation persists after nonsurgical therapy. There are three main surgical approaches: access surgery for surface decontamination, resective surgery to remove pathological pockets and improve hygiene access in non-regenerative defects, and reconstructive surgery to promote bone regeneration and re-osseointegration in defects with regenerative potential²⁵.

1) Access surgery

It enhances nonsurgical treatment by allowing direct surface debridement through flap elevation. Widely used in periodontitis and peri-implantitis, its long-term efficacy is established. The success of access surgery has improved with advanced surface decontamination techniques, including local minocycline delivery, titanium-coated curettes, copper-alloy ultrasonic scalers, titanium brushes, and air-powder abrasives. Though more conservative than resective surgery, it carries a risk of mucosal recession due to flap elevation²⁵.

2) Resective surgery

It is used for non-regenerative defects, such as non-contained and supracrestal defects. It includes bone recontouring, apically positioned flaps, and implantoplasty. Implantoplasty smooths exposed implant

threads with a high-speed bur, reducing biofilm accumulation and bacterial regrowth without compromising biocompatibility. Thorough irrigation is essential to remove titanium particles that may cause biological complications²⁶. Implantoplasty also risks fracture, especially in narrow-diameter implants with internal connections²⁷. Englezos et al. reported favorable outcomes over two years using an apically positioned flap, osteoplasty, and implantoplasty in severe peri-implantitis cases with significant bone loss²⁸.

3) Reconstructive surgery

It follows the same surface decontamination process as access surgery but involves filling bone defects with graft materials. The suitability of bone defects for regeneration is crucial. Monje et al. found that 58% of peri-implantitis bone defects, particularly circumferential and infraosseous defects, had regenerative potential²⁹. Graft use results in greater radiographic defect fill compared to access or resective surgery²⁴. Reconstructive surgery significantly reduces probing depth and minimizes mucosal recession due to graft support²⁵. However, inflammation resolution is similar to access or resective surgery. Long-term bone stability improves with growth factors like enamel matrix derivatives and platelet-derived growth factor .

In the case of defects with both intraosseous and supracrestal components, combined surgery—resective for the supracrestal part and regenerative for the intraosseous part—may be used. In a recent study based on CBCT analysis, around 20% of the peri-implantitis defects had combined horizontal and intraosseous defect configurations²⁹. Schwarz et al. combined implantoplasty for the supracrestal area with regeneration using bone mineral and collagen membrane, achieving over 85% BOP reduction and >2 mm clinical attachment gain over 7 years³⁰. Studies showed that combined surgery with

titanium brush decontamination reduced probing depth by 3–4 mm and achieved ~80% bone fill in 12 months²⁵. Soft tissue quality can be improved surgically, as adequate peri-implant mucosa is essential for maintaining peri-implant health. Insufficient keratinized mucosa (<2 mm) and shallow vestibular depth hinder plaque control and cause discomfort^{1,31}. Thin mucosa also compromises the mucosal seal and marginal bone stability³². Soft tissue augmentation with autogenous grafts or collagen substitutes enhances peri-implant conditions. An apically positioned flap with a free gingival graft is preferred for increasing keratinized mucosa, while connective tissue grafts or collagen substitutes improve mucosal thickness. A systematic review found a lower peri-implantitis prevalence in implants with soft tissue augmentation³³.




Figure 5: Surgical treatment for peri-implantitis

Challenges in Peri-Implantitis Management

Peri-implantitis remains a major challenge in implantology due to its complex causes, unpredictable progression, and lack of consensus on optimal management. Treatment is complicated by factors such as delayed diagnosis, biofilm resistance, patient-specific risks, and the limitations of existing therapies.

1. Difficulty in Early Diagnosis: A major challenge in managing peri-implantitis is the absence of a universally accepted definition and diagnostic criteria. Early-stage peri-implantitis is often asymptomatic, making detection difficult². Clinically, it involves bone loss and inflammation, but differentiating between physiological remodeling and pathological loss remains problematic³.

Furthermore, the lack of standardized probing thresholds leads to inconsistencies in diagnosing the disease⁸.

2. **Biofilm Resistance and Implant Surface Contamination:** Peri-implantitis biofilm is highly resistant to debridement due to its complex structure and strong adhesion to rough implant surface³⁴. Even with antimicrobial therapies, complete decontamination is difficult, leading to persistent bacteria and disease recurrence despite treatment efforts²⁴.

3. **Limitations of Non-Surgical and Surgical Treatments:** Non-surgical treatments like mechanical debridement and antiseptic rinses show limited success in eliminating peri-implant biofilms, especially in deep lesions³. Surgical approaches, including resective and regenerative techniques, have variable outcomes influenced by defect morphology, implant surface, and patient factors³⁵. However, regenerative therapies remain unpredictable due to inconsistent bone regeneration and challenges in achieving stable soft tissue sealing.

4. **Patient-Related Risk Factors:** Various systemic and behavioral factors increase susceptibility to peri-implantitis and complicate its management. A history of periodontitis elevates the risk due to microbial imbalance and immune response changes³⁶. Smoking, diabetes, and poor oral hygiene further impair healing and immune function, worsening inflammation. Additionally, poor adherence to maintenance care increases the likelihood of reinfection and implant failure³⁷.

5. **Implant Design and Material Considerations:** Implant surface modifications, intended to improve osseointegration, can also increase peri-implantitis risk by facilitating bacterial adhesion³⁸. Factors like surface roughness, thread design, and material composition affect plaque buildup and biofilm retention, influencing long-term implant health³⁹. Additionally, titanium corrosion

and particle release have been linked to peri-implant inflammation and bone loss⁴⁰.

6. **Lack of Standardized Treatment Protocols:** No universally accepted treatment protocol exists for peri-implantitis, with approaches varying from mechanical decontamination to surgical interventions². The effectiveness of adjunctive therapies, including antibiotics and growth factors, remains uncertain due to inconsistent clinical data⁴¹. This lack of consensus complicates treatment decisions and leads to variable outcomes.

7. **High Risk of Recurrence and Implant Failure:** Despite aggressive treatment, peri-implantitis has a high recurrence rate, with failure rates reaching up to 40% within five years. This is due to persistent bacterial colonization, poor soft tissue sealing, and challenges in fully resolving defects. Additionally, failed implants often require complex revisions, such as bone grafting and implant replacement, increasing both the financial and biological burden^{1,2,3}.

8. **Financial and Psychological Burden on Patients:** Managing peri-implantitis is costly and time-consuming, involving multiple treatments and ongoing maintenance. Implant failure can also cause psychological distress, especially when implants serve esthetic or functional purposes. The lack of insurance coverage for complications adds to the financial strain on patients³⁷.

Prevention Strategies in Peri-Implantitis Management

Peri-implantitis is a major challenge in implant dentistry, leading to bone loss and implant failure. Prevention is crucial for long-term success. This review covers evidence-based strategies, including patient and implant selection, surgical protocols, prosthetic considerations, and long-term maintenance.

1. Patient Selection and Risk Factor Assessment: A key factor in preventing peri-implantitis is identifying and managing patient-related risk factors. A history of periodontitis increases the risk of peri-implant disease; as previous periodontal issues can lead to compromised implant health². Smoking is another significant risk factor, as smokers tend to experience higher implant failure rates due to impaired healing and increased biofilm accumulation around the implant⁴². Poorly controlled diabetes also elevates the risk, as it negatively impacts immune function and wound healing, making patients more susceptible to peri-implantitis¹⁰. Additionally, poor oral hygiene compliance plays a critical role, as patients with inadequate plaque control are more prone to peri-implant inflammation and subsequent complications⁴³.

2. Implant Selection and Surface Modifications: Implant design plays a crucial role in plaque accumulation and peri-implant health. While roughened surfaces promote osseointegration, they also facilitate bacterial adhesion. Antibacterial coatings, such as silver and chitosan, can reduce microbial colonization. Zirconia implants, which exhibit lower bacterial adhesion compared to titanium, may be advantageous for high-risk patients⁴⁴.

3. Optimizing Surgical Protocols: Surgical protocols are essential for maintaining peri-implant health. Minimally invasive techniques, such as flapless surgery, help reduce trauma and bacterial contamination. Proper implant positioning prevents excessive bone remodeling and soft tissue recession. Additionally, preserving keratinized tissue (≥ 2 mm) is linked to lower levels of peri-implant inflammation⁴⁵.

4. Prosthetic Considerations for Peri-Implant Health: Screw-retained restorations lower the risk of cement-induced peri-implantitis. A convex emergence profile makes cleaning easier and helps reduce plaque buildup.

Additionally, avoiding overcontoured restorations enhances access for proper hygiene⁴⁶.

5. Peri-Operative and Post-Operative Antibiotic Use: Pre-operative antibiotics, such as 2g of amoxicillin 1 hour before surgery, may reduce the risk of early infection. However, prolonged antibiotic use should be avoided to prevent the development of antibiotic resistance⁴⁷.

6. Long-Term Maintenance and Supportive Care: Professional maintenance every 3–6 months helps prevent biofilm buildup around implants⁴⁸. Air-polishing with glycine or erythritol powder effectively removes biofilm without harming the implant surface. Routine peri-implant probing and radiographs are essential for early disease detection. Educating patients on using interdental brushes and chlorhexidine mouth rinses can significantly improve peri-implant hygiene⁴⁹.

7. Future Directions in Peri-Implantitis Prevention: Emerging treatments include photodynamic therapy (PDT) for controlling biofilm, smart implants that release antimicrobials upon detecting inflammation, and the use of salivary biomarkers for early detection of peri-implant inflammation^{50,51,52}.

Future Directions and Research Gaps

Peri-implantitis remains a significant challenge in implant dentistry, with current treatments showing variable success rates. Future research aims to develop innovative prevention, diagnostic, and treatment strategies to enhance long-term implant survival. This review highlights emerging technologies and existing research gaps in peri-implantitis management.

1. Need for Standardized Treatment Protocols: The lack of standardized treatment guidelines in peri-implantitis management results in inconsistent treatment success. Key areas requiring standardization include Establishing standardized diagnostic criteria is essential to create a consensus on peri-implantitis classification, improving

comparability across studies. Additionally, defining the most effective non-surgical decontamination methods, such as air-polishing, laser therapy, and antimicrobial agents, will enhance treatment predictability⁴⁹. Surgical approaches also require optimization, particularly in selecting the best regenerative techniques, including flap surgery and guided bone regeneration⁵³. Developing standardized clinical protocols will promote evidence-based treatment strategies, leading to improved patient outcomes.

2. **Advances in Regenerative Medicine and Personalized Therapy:** Regenerative medicine aims to restore lost bone and soft tissue around implants. Recent advancements include Biological growth factors, such as bone morphogenetic proteins (BMPs) and platelet-derived growth factors, play a crucial role in enhancing tissue healing and regeneration. The development of 3D-printed scaffolds, loaded with bioactive molecules, offers a promising approach for bone regeneration around implants. Additionally, stem cell therapy, particularly using mesenchymal stem cells, is being explored for its potential in regenerating peri-implant bone defects. Additionally, personalized treatment approaches using genetic risk assessment and microbiome analysis could help identify patients at high risk for peri-implantitis, allowing for targeted preventive and therapeutic strategies⁵³.

3. Long-Term Studies on Peri-Implantitis Outcomes

Despite extensive research, long-term clinical data on peri-implantitis management remain limited. Areas needing further investigation include Assessing implant survival rates is essential for understanding the long-term prognosis of different peri-implantitis treatments⁵⁴. Comparative studies evaluating the effectiveness of non-surgical versus surgical interventions can provide insights into the best approaches for preventing disease

recurrence⁹. Additionally, systemic health factors such as diabetes, osteoporosis, and immune disorders play a crucial role in peri-implant disease progression and treatment response, highlighting the need for further research on their impact⁵⁵. Long-term, multicenter randomized controlled trials (RCTs) are needed to validate current therapies and guide clinical decision-making.

Conclusion

Peri-implantitis remains a significant challenge in implant dentistry, requiring a comprehensive approach. While nonsurgical treatments have limited success, surgical methods incorporating surface decontamination and bone regeneration show better outcomes. However, achieving complete biofilm removal and re-osseointegration is difficult, and the absence of standardized diagnostic criteria complicates early detection. Future research should focus on standardized protocols and innovative therapies like antimicrobial coatings and regenerative techniques. Emphasizing prevention through patient education, early diagnosis, and tailored treatment strategies is crucial for reducing peri-implantitis cases and ensuring long-term implant success.

References

1. Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, Chen S, Cochran D, Derks J, Figuero E, Hämmerle CH. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *Journal of clinical periodontology*. 2018 Jun;45:S286-91.
2. Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. *Journal of clinical periodontology*. 2018 Jun;45:S246-66.

3. Renvert S, Persson GR, Pirih FQ, Camargo PM. Peri-implant health, peri-implant mucositis, and peri-implantitis: Case definitions and diagnostic considerations. *Journal of clinical periodontology*. 2018 Jun;45:S278-85.
4. Derks J, Schaller D, Håkansson J, Wennström JL, Tomasi C, Berglundh T. Effectiveness of implant therapy analyzed in a swedish population: prevalence of peri-implantitis. *J Dent Res* 2016;95:43-9.
5. Derks J, Schaller D, Håkansson J, Wennström JL, Tomasi C, Berglundh T. Peri-implantitis - onset and pattern of progression. *J Clin Periodontol* 2016;43:383-8.
6. Araujo MG, Lindhe J. Peri-implant health. *J Periodontol* 2018;89 Suppl 1:S249-56.
7. Mombelli A, Lang NP. The diagnosis and treatment of peri-implantitis. *Periodontol* 2000 1998;17:63-76.
8. Heitz-Mayfield LJA, Salvi GE. ITI treatment guide volume 13- prevention and management of peri-implant diseases. Batavia: Quintessence Publishing
9. Sinjab K, Garaicoa-Pazmino C, Wang HL. Decision making for management of periimplant diseases. *Implant Dent* 2018;27:276-81.
10. Monje A. Unfolding peri-implantitis. *The International Journal of Esthetic Dentistry*. 2023 Jul 1;18(3):311-.
11. Renvert S, Roos-Jansåker AM, Claffey N. Non-surgical treatment of peri-implant mucositis and peri implantitis: a literature review. *J Clin Periodontol* 2008;35 Suppl:305-15.
12. Park SH, Song YW, Cha JK, Lee JS, Kim YT, Shin HS, et al. Adjunctive use of metronidazole-minocycline ointment in the nonsurgical treatment of peri-implantitis: a multicenter randomized controlled trial. *Clin Implant Dent Relat Res* 2021;23:543-54. Epub 2021 Jun 18.
13. Heitz-Mayfield LJ, Heitz F, Lang NP. Implant disease risk assessment IDRA-a tool for preventing peri implant disease. *Clin Oral Implants Res* 2020;31:397-403.
14. Meffert RM. How to treat ailing and failing implants. *Implant Dent* 1992;1:25-33.
15. Scarano A, Carinci F, Quaranta A, Iezzi G, Piattelli M, Piattelli A. Correlation between implant stability quotient (ISQ) with clinical and histological aspects of dental implants removed for mobility. *Int J Immunopathol Pharmacol* 2007;20 Suppl 1:33-6.
16. Okayasu K, Wang HL. Decision tree for the management of periimplant diseases. *Implant Dent* 2011;20:256-61.
17. Ravidà A, Siqueira R, Di Gianfilippo R, Kaur G, Giannobile A, Galindo-Moreno P, et al. Prognostic factors associated with implant loss, disease progression or favorable outcomes after peri-implantitis surgical therapy. *Clin Implant Dent Relat Res* 2022;24:222-32.
18. Park YS, Lee BA, Choi SH, Kim YT. Evaluation of failed implants and reimplantation at sites of previous dental implant failure: survival rates and risk factors. *J Periodontal Implant Sci* 2022;52:230-41.
19. Jepsen S, Berglundh T, Genco R, Aass AM, Demirel K, Derks J, et al. Primary prevention of peri-implantitis: managing peri-implant mucositis. *J Clin Periodontol* 2015;42 Suppl 16:S152-7.
20. Ramanauskaite A, Fretwurst T, Schwarz F. Efficacy of alternative or adjunctive measures to conventional non-surgical and surgical treatment of peri-implant mucositis and peri-implantitis: A systematic review and meta-analysis. *International journal of implant dentistry*. 2021 Dec;7:1-61.

21. Kim HJ, Ahn DH, Yu Y, Han H, Kim SY, Joo JY, et al. Microbial profiling of peri-implantitis compared to the periodontal microbiota in health and disease using 16S rRNA sequencing. *J Periodontal Implant Sci* 2023;53:69-84.
22. Nart J, Pons R, Valles C, Esmatges A, Sanz-Martin I, Monje A. Non-surgical therapeutic outcomes of peri implantitis: 12-month results. *Clin Oral Investig* 2020;24:675-82.
23. De Tapia B, Mozas C, Valles C, Nart J, Sanz M, Herrera D. Adjunctive effect of modifying the implant supported prosthesis in the treatment of peri-implant mucositis. *J Clin Periodontol* 2019;46:1050-60.
24. Korello K, Eickholz P, Zuhr O, Ratka C, Petsos H. In vitro efficacy of non-surgical and surgical implant surface decontamination methods in three different defect configurations in the presence or absence of a suprastructure. *Clin Implant Dent Relat Res* 2023;25:549-63.
25. Schwarz F, Jepsen S, Obreja K, Galarraga-Vinueza ME, Ramanauskaite A. Surgical therapy of peri implantitis. *Periodontol 2000* 2022;88:145-81.
26. Mombelli A, Hashim D, Cionca N. What is the impact of titanium particles and biocorrosion on implant survival and complications? *Crit Rev* 2018;29:37-53.
27. Bertl K, Isidor F, von Steyern PV, Stavropoulos A. Does implantoplasty affect the failure strength of narrow and regular diameter implants? A laboratory study. *Clin Oral Investig* 2021;25:2203-11.
28. Englezos E, Cosyn J, Koole S, Jacquet W, De Bruyn H. Resective treatment of peri-implantitis: clinical and radiographic outcomes after 2 years. *Int J Periodont Restor Dent* 2018;38:729-35.
29. Monje A, Pons R, Insua A, Nart J, Wang HL, Schwarz F. Morphology and severity of peri-implantitis bone defects. *Clin Implant Dent Relat Res* 2019;21:635-43.
30. Schwarz F, John G, Schmucker A, Sahm N, Becker J. Combined surgical therapy of advanced peri implantitis evaluating two methods of surface decontamination: a 7-year follow-up observation. *J Clin Periodontol* 2017;44:337-42.
31. Perussolo J, Souza AB, Matarazzo F, Oliveira RP, Araújo MG. Influence of the keratinized mucosa on the stability of peri-implant tissues and brushing discomfort: a 4-year follow-up study. *Clin Oral Implants Res* 2018;29:1177-85.
32. Gharpure AS, Latimer JM, Aljofi FE, Kahng JH, Daubert DM. Role of thin gingival phenotype and inadequate keratinized mucosa width (< 2 mm) as risk indicators for peri-implantitis and peri-implant mucositis. *Journal of Periodontology*. 2021 Dec;92(12):1687-96.
33. Stefanini M, Barootchi S, Sangiorgi M, Pispero A, Grusovin MG, Mancini L, et al. Do soft tissue augmentation techniques provide stable and favorable peri-implant conditions in the medium and long term? A systematic review. *Clin Oral Implants Res* 2023;34 Suppl 26:28-42.
34. Sánchez MC, Llama-Palacios A, Fernández E, Figuero E, Marín MJ, León R, Blanc V, Herrera D, Sanz M. An in vitro biofilm model associated to dental implants: Structural and quantitative analysis of in vitro biofilm formation on different dental implant surfaces. *Dental Materials*. 2014 Oct 1;30(10):1161-71.
35. Carcuac O, Derks J, Abrahamsson I, Wennström JL, Berglundh T. Risk for recurrence of disease following surgical therapy of peri-implantitis—A

- prospective longitudinal study. Clinical oral implants research. 2020 Nov;31(11):1072-7.
36. Monje A, Catena A, Borgnakke WS. Association between diabetes mellitus/hyperglycaemia and peri-implant diseases: systematic review and meta-analysis. *Journal of clinical periodontology*. 2017 Jun;44(6):636-48.
37. Serino G, Hultin K. Periimplant disease and prosthetic risk indicators: a literature review. *Implant dentistry*. 2019 Apr 1;28(2):125-37.
38. Aljateeli M, Fu JH, Wang HL. Managing peri-implant bone loss: current understanding. *Clin Implant Dent Relat Res*. 2020;22(5):595-609.
39. Kotsakis GA, Olmedo DG. Foreign body reactions to dental biomaterials. *Periodontol* 2000. 2021;86(1):99-112.
40. Barrak FN, Li S. Titanium wear particles and peri-implant inflammation. *J Dent Res*. 2020;99(3):259-66.
41. de Waal YC, Raghoobar GM, Huddleston Slater JJ, Meijer HJ, Winkel EG. Implant decontamination with lasers and airflow therapy. *Clin Oral Implants Res*. 2021;32(7):875-90.
42. Chrcanovic BR, Albrektsson T, Wennerberg A. Smoking and dental implants: a systematic review and meta-analysis. *Journal of dentistry*. 2015 May 1;43(5):487-98.
43. Figuero E, Graziani F, Sanz I, et al. Management of peri-implant mucositis and peri-implantitis. *Periodontol 2000*. 2014;66(1):255-73.
44. Almeslet AS, Aljudaibi SM. Peri-implant clinical profile and subgingival yeasts carriage among cigarette-smokers with peri-implant mucositis. *BMC Oral Health*. 2024 Oct 29;24(1):1312.
45. Romero-Ruiz MM, Mosquera-Perez R, Gutierrez-Perez JL, Torres-Lagares D. Flapless implant surgery: A review of the literature and 3 case reports. *Journal of clinical and experimental dentistry*. 2015 Feb 1;7(1):e146.
46. Chankhore P, Khubchandani SR, Reche A, Paul P. Prosthetic design factors influencing peri-implant disease: a comprehensive review. *Cureus*. 2023 Nov 13;15(11).
47. Salgado-Peralvo AO, Peña-Cardelles JF, Kewalramani N, Mateos-Moreno MV, Jiménez-Guerra Á, Velasco-Ortega E, Uribarri A, Moreno-Muñoz J, Ortiz-García I, Núñez-Márquez E, Monsalve-Guil L. Preventive antibiotic therapy in the placement of immediate implants: A systematic review. *Antibiotics*. 2021 Dec 22;11(1):5.
48. Araújo TG, Moreira CS, Neme RA, Luan H, Bertolini M. Long-term Implant Maintenance: A Systematic Review of Home and Professional Care Strategies in Supportive Implant Therapy. *Brazilian Dental Journal*. 2024 Oct 25;35:e24-6178.
49. Perussolo J, Donos N. Maintenance of peri-implant health in general dental practice. *British dental journal*. 2024 May 24;236(10):781-9.
50. Rahman B, Acharya AB, Siddiqui R, Verron E, Badran Z. Photodynamic therapy for peri-implant diseases. *Antibiotics*. 2022 Jul 8;11(7):918.
51. Montoya C, Roldan L, Yu M, Valliani S, Ta C, Yang M, Orrego S. Smart dental materials for antimicrobial applications. *Bioactive Materials*. 2023 Jun 1;24:1-9.
52. Lumbikananda S, Srithanyarat SS, Mattheos N, Osathanon T. Oral fluid biomarkers for peri-implantitis: a scoping review. *International Dental Journal*. 2024 Jun 1;74(3):387-402.
53. Marian D, Toro G, D'Amico G, Trotta MC, D'Amico M, Petre A, Lile I, Hermenean A, Fratila A. Challenges and Innovations in Alveolar Bone

Regeneration: A Narrative Review on Materials, Techniques, Clinical Outcomes, and Future Directions. *Medicina*. 2024 Dec 27;61(1):20.

54. Romandini M, Bougas K, Alibegovic L, Hosseini S, Carcuac O, Berglundh T, Derks J. Long-term outcomes and prognostic factors of surgical treatment of peri-implantitis—A retrospective study. *Clinical Oral Implants Research*. 2024 Mar;35(3):321-9.

55. Radaelli K, Alberti A, Corbella S, Francetti L. The impact of peri-implantitis on systemic diseases and conditions: a review of the literature. *International Journal of Dentistry*. 2021;2021(1):5536566.